Peter Breingan, MD
Ophthalmology · Manhasset, NYNPI 1770568560
Payments from drug & device makers
Across 215 payments — averaging $25.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$949
- Alcon$827
- Oyster Point Pharma, Inc.$605
- Novartis$567
- NEW World Medical,inc.$320
- Bausch & Lomb Americas Inc.$305
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,500100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $949 |
| Alcon | 28 | $827 |
| Oyster Point Pharma, Inc. | 26 | $605 |
| Novartis | 19 | $567 |
| NEW World Medical,inc. | 2 | $320 |
| Bausch & Lomb Americas Inc. | 16 | $305 |
| Harrow Eye, LLC | 12 | $290 |
| Sun Pharmaceutical Industries Inc. | 12 | $243 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $231 |
| Kala Pharmaceuticals, Inc. | 12 | $217 |
| Aerie Pharmaceuticals, Inc. | 8 | $141 |
| Tarsus Pharmaceuticals, Inc. | 5 | $126 |
| Thea Pharma Inc. | 5 | $104 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $91 |
| Eyevance Pharmaceuticals LLC | 4 | $79 |
| Amgen | 4 | $74 |
| Mallinckrodt Hospital Products Inc. | 2 | $63 |
| Rxsight Inc | 2 | $54 |
| Ocular Therapeutix, Inc. | 3 | $52 |
| Shire North American Group Inc | 2 | $45 |
| Rayner Intraocular Lenses Limited | 2 | $33 |
| Biotissue Holdings Inc. | 1 | $25 |
| Eyepoint US, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $19 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $18 |
| Sight Sciences, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$359
- Ahmed Glaucoma Valve$320
- Kahook Dual Blade$320
- Clareon$271
- Streamline Surgical System$184
- XIIDRA$125
- LOTEMAX SM$100
How this compares
$5,518 in reported general payments places this provider in the 75th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 155 | $158,233 |
| XiidraLifitegrast | 41 | $55,737 |
| LumiganBimatoprost | 68 | $37,950 |
| MieboPerfluorohexyloctane/Pf | 33 | $29,387 |
| Cyclosporine | 64 | $25,320 |
| BesivanceBesifloxacin Hcl | 89 | $19,066 |
| ProlensaBromfenac Sodium | 56 | $16,840 |
| TyrvayaVarenicline Tartrate | 25 | $15,131 |
| Restasis MultidoseCyclosporine | 20 | $12,814 |
| InveltysLoteprednol Etabonate | 45 | $12,692 |
| Prednisolone Acetate | 338 | $9,503 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $6,597 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $6,219 |
| RhopressaNetarsudil Mesylate | 19 | $5,669 |
| Latanoprost | 522 | $5,667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan, Alphagan P | $949 | $219,421275 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $305 | $85,12474 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa | $231 | $35,906145 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $605 | $15,13125 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $217 | $12,69245 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $141 | $12,26631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Manhasset
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.